Senseonics Holdings stock
SENSNASDAQSenseonics Holdings, Inc., HealthcareISIN US81727U3032
44Score 44 out of 100, Weak
Price and trend
84 / 100
Price history
+60% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 43% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 72).
The price is at its 52-week high. Largest decline in 11 years: 95% (February 2021 to July 2026).
Chart figures for advanced users
- SMA 50$9.16
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.86
- The lowest closing price of the last twelve months.
- Resistance$10.42
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Senseonics Holdings, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $684.97M, is number 71 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $35.26M (up 56.9% year on year) and a loss of $69.11M.
- For fiscal 2026, analysts expect on average revenue of $64.24M (up 82.2%) and adjusted earnings per share of −$2.28.
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 491 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 266% since 2020.Capital allocation 18
- Loss-makingLoss of $122.54M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 82% a year over the last 12 months.Stability 45
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 105% on the twelve months before. Up to 2021 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 0.6% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 45%, operating −194%, net −196%. Last 12 months: net −100%. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 9 Nov 2026EPS reported −$0.50 (expected −$0.52)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.280.0%
- Revenue
- $64.24M0.0%
- Earnings per share
- −$1.930.0%
- Revenue
- $99.98M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −6.2%2026 revenue guidance raised to $60 million to $64 million from $58 million to $62 million.
“Given all of this, we are raising our full year 2026 global net revenue guidance to $60 million to $64 million from $58 million to $62 million, representing year-over-year growth of 70% to 82%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $125,300 in total.
- Roeder Douglas APurchase
19 Aug 2026, Board
- Shares
- 13,953.28
- Price
- $8.98
- Value
- $125,300
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Senseonics Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Delcath SystemsDCTH $757.34M64
- Cytek BiosciencesCTKB $753.32M47
- BioventusBVS $752.53M61
- Synektik Spólka AkcyjnaSNT.WA $709.44M77
- Xvivo PerfusionXVIVO.ST $653.35M50
- Pacific Biosciences of CaliforniaPACB $649.64M38
- Tactile Systems TechnologyTCMD $607.75M68
- Sight SciencesSGHT $606.92M48
ETFs that hold Senseonics Holdings
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.